Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 5 Cytokine Release Syndrome 4 Lymphoma, Non-Hodgkin 3 Neoplasms, Plasma Cell 2 Thrombocytosis 1 Thrombocytopenia 1 Schwannomatosis 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pancreatic Neoplasms 1 Pain 1 Neurilemmoma 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Large Granular Lymphocytic 1 Immunoglobulin Light-chain Amyloidosis 1 Chronic Pain 1 Anemia 1 Advanced Malignant Solid Neoplasm 1

Interventions

Cytarabine 358 Cyclophosphamide 241 Azacitidine 213 fludarabine phosphate 199 venetoclax 198 fludarabine 196 Busulfan 148 Decitabine 132 Mycophenolic Acid 123 Whole-Body Irradiation 122 Peripheral Blood Stem Cell Transplantation 118 Tacrolimus 115 Granulocyte Colony-Stimulating Factor 104 Idarubicin 100 Filgrastim 100 Melphalan 89 Cyclosporine 89 Methotrexate 83 Daunorubicin 76 Antilymphocyte Serum 75 Etoposide 73 Mitoxantrone 67 Clofarabine 67 Gemtuzumab 59 Stem Cell Transplantation 55 Thiotepa 51 Cladribine 46 Injections 45 Specimen Handling 44 thymoglobulin 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Leukemia, Myeloid, Acute × siltuximab × Clear all

NCT05697510 2023-04-06

SILTUXILAM

Nantes University Hospital

Phase 1 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡